(Q35184558)

7 August 2017

1 reference

title

Hepatotoxicity of the thiazolidinediones (English)

1 reference

7 August 2017

1 reference

Keith G Tolman

1

1 reference

PubMed ID

12879989

7 August 2017

Jane Chandramouli

series ordinal

2

1 reference

PubMed ID

12879989

7 August 2017

language of work or name

1 reference

1 May 2003

1 reference

7 August 2017

Clinics in liver disease

1 reference

7 August 2017

7

1 reference

7 August 2017

369-79, vi

1 reference

7 August 2017

2

1 reference

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

The prevalence of multiple diabetes-related complications

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

In vitro studies on the action of CS-045, a new antidiabetic agent

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Thiazolidinediones: a new class of antidiabetic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Thiazolidinediones--the new insulin enhancers

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

1 reference

7 January 2021

Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Glyburide-induced hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Severe hepatotoxicity associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

An autopsy case of troglitazone-induced fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Troglitazone-associated hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Fatal hepatotoxicity associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Metformin-induced acute hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Hepatic failure in a patient taking rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Rosiglitazone toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Hepatocellular injury in a patient receiving rosiglitazone. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Liver failure in a patient treated with long-term rosiglitazone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Hepatocellular injury in a patient receiving pioglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Pioglitazone-associated fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Quinone toxicity in hepatocytes: studies on mitochondrial Ca2+ release induced by benzoquinone derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Protective effect of ethanol against acetaminophen-induced hepatotoxicity in mice: role of NADH:quinone reductase

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Nonalcoholic Steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Association of diabetes mellitus and chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Hepatic injury caused by acarbose

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Acarbose-induced acute hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Acarbose-induced acute severe hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Toxicological studies on carbutamide

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Intrahepatic cholestasis following administration of chlorpropamide. Report of a case with electron microscopic observations

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Cholestatic jaundice following chlorpropamide self-poisoning

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Chlorpropamide-induced granulomas. A probable hypersensitivity reaction in liver and bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Granulomatous hepatitis associated with glyburide

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Liver enzyme monitoring in patients treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

The infrequency of liver function testing in patients using nonsteroidal anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

Contraindicated use of cisapride: impact of food and drug administration regulatory action

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900020-5

7 January 2021

10.1016/S1089-3261(03)00020-5

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12879989